- Addresses all new monoclonal antibodies for treating migraine
- Analyses the entire path – from discovery to pharmacology, human and animal models, and the four molecules in the grou
- Places major emphasis on real-world data emerging after the official guidelines
Intended to promote a more appropriate and modern therapeutic approach to migraine management, this book is the first to deal with monoclonal antibodies in this context.
Authored by the most respected migraine experts from around the globe and drawing on the lessons learned in both clinical trials and clinical practice, it reviews the current state of knowledge on this important therapeutic innovation, which has produced impressive data in randomized controlled trials, and the efficacy and safety of which have been confirmed in day-to-day real-world use.
Given its scope, the book will appeal to a broad range of specialists, including pharmacologists, clinical pharmacologists, neurologists and internists, but also to residents and medical students.
Table of Contents- The CGRP Family of Neuropeptides and their Receptors in the Trigeminovascular System
- Pharmacology; Where Do the
- Monoclonal Antibody Biology
- Guidelines for Clinical Trials
- Human
CGRP Antibodies for Animal Models of Primary and Secondary Headache Disorders - Galcanezumab
- Eptinezuma
- Erenumab
- Fremanezumab
- Potential Side Effects and Pregnancy
- Real-World Data, Clinical Practice So Far
- Migraine Versus Cluster Headache and Potential Other Indications
